Induction of the tumor-suppressor p16INK4a within regenerative epithelial crypts in ulcerative colitis

Neoplasia

Volumn 8, Issue 6, 2006, Pages 429-436

  Furth, Emma E ^a   Gustafson, Karen S ^a   Dai, Charlotte Y ^a   Gibson, Steven L ^a   Menard Katchery, Paul ^a   Chen, Tina ^a   Koh, Jim ^b   Enders, Greg H ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CRB   (United States)

Author keywords

DNA damage; INK4a; p16; Tumor suppressor; Ulcerative colitis

Indexed keywords

PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRYPT CELL; DNA DAMAGE; EPITHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VIVO STUDY; KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; STRESS; ULCERATIVE COLITIS;

EID: 33745845132     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06169     Document Type: Article

References (52)

1. Lowe SW and Sherr CJ (2003). Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13, 77-83.
2. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, and DePinho RA (2004). The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 23 (2), 379-385.
3. Herman JG (1999). p16(INK4): involvement early and often in gastrointestinal malignancies. Gastroenterology 116 (2), 483-485.
4. Sharpless NE, Bardeesy N, Lee KH, Carrasca D, Castrillion DH, Aguirre AJ, Wu EA, Horner JW, and DePinho RA (2001). Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413 (6851), 86-91.
5. Zindy F, Quelle DE, Roussel MF, and Sherr CJ (1997). Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15 (2), 203-211.
6. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, and Sharpless NE (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114 (9), 1299-1307.
7. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J, and Louis DN (1999). Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest 79 (9), 1137-1143.
8. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y, and Enders GH (2000). p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 119 (4), 929-942.
9. Milligan A, Gabrielli BG, Clark JM, Hayward NK, and Ellem KA (1998). Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation. Mutat Res 422 (1), 43-53.
10. Pavey S, Conroy S, Russell T, and Gabrielli B (1999). Ultraviolet radiation induces p16CDKN2A expression in human skin. Cancer Res 59 (17), 4185-4189.
11. Ramirez RD, Morales CP, Herbert BS, Rohde JM, Passons C, Shay JW, and Wright WE (2001). Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev 15 (4), 398-403.
12. Lessard J and Sauvageau G (2003). Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423 (6937), 255-260.
13. Herman JG, Merlo A, Lapidus RG, Issa J-P, Davidson NE, Sidransky D, and Baylin SB (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55, 4525-4530.
14. Wiencke JK, Zheng S, Lafuente A, Lafuente MJ, Gradzen C, Wrensch MR, Miike R, Ballest A, and Trias M (1999). Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomark Prev 8 (6), 501-506.
15. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, and Issa JP (1999). CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96 (15), 8681-8686.
16. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, and Jones PA (1995). Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55 (20), 4531-4535.
17. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, and Reid BJ (1999). Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22 (1), 106-109.
18. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, and Porschen R (1998). Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 58 (17), 3942-3945.
19. Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, McDermott K, Kozakiewicz K, and Gauthier ML (2004). Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia 9 (3), 263-274.
20. Crawford YG, Gauthier ML, Joubel A, Mantzi K, Kozakiewicz K, Afshari CA, and Tlsty TD (2004). Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 5 (3), 263-273.
21. Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin SB, Herman JO, and Tlsty TD (2003). Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 63 (7), 1596-1601.
22. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, DiTullio RA Jr, Kastrinakis NG, Levy B, et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (7035), 907-913.
23. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (7035), 864-870.
24. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, and Lofberg R (2000). A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47 (3), 404-409.
25. Burns KL, Ueki K, Jhung SL, Koh J, and Louis DN (1998). Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57 (2), 122-130.
26. Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M, and Rustgi AK (2003). Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem 278 (3), 1824-1830.
27. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, and Enders GH (1999). Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol 19 (5), 3916-3928.
28. Diebold J, Dopfer K, Lai M, and Lohrs U (1994). Comparison of different monoclonal antibodies for the immunohistochemical assessment of cell proliferation in routine colorectal biopsy specimens. Scand J Gastroenterol 29 (1), 47-53.
29. Berenzi A, Benetti A, Bertalot G, Rodolfi A, Portolani N, Giulini SM, Pulcini G, Vinco A, and Tiberio G (1992). Ki67 immunohistochemical evaluation in colorectal cancer and normal colonic mucosa. Possible clinical applications. Pathologica 84 (1090), 155-163.
30. Doglioni C, Pelosio P, Laurino L, Macri E, Meggiolaro E, Favretti F, and Barbareschi M (1996). P21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 179 (3), 248-253.
31. Yoshida T, Matsumoto N, Mikami T, and Okayasu I (2004). Upregulation of p16(INK4A) and Bax in p53 wild/p53 - overexpressing crypts in ulcerative colitis - associated tumours. Br J Cancer 91 (6), 1081-1088.
32. Bakkenist CJ and Kastan MB (2003). DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 (6922), 499-506.
33. Kalabis J, Patterson MJ, Enders GH, Marian B, Iozzo RV, Rogier G, Gimotty PA, and Herlyn M (2003). Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture. FASEB J 17 (9), 1115-1117.
34. Baylin SB, Herman JG, Graff JR, Vertino PM, and Issa J-P (1998). Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72, 141-196.
35. Hu B, Mitra J, Heuvel SVD, and Enders G (2001). S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant negative mutant in human cells. Mol Cell Biol 21 (8), 2755-2766.
36. Geradts J and Wilson PA (1996). High frequency of aberrant p16INK4A expression in human breast carcinoma. Am J Pathol 149 (1), 15-20.
37. Milde-Langosch K, Riethdorf L, Bamberger AM, and Loning T (1999). p16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch 434 (1), 23-28.
38. Geradts J, Hruban RH, Schutte M, Kern SE, and Maynard R (2000). Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol 8 (1), 71-79.
39. Hara E, Smith R, Parry D, Tahara H, Stone S, and Peters G (1996). Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16 (3), 859-867.
40. Reznikoff CA, Yeager TR, Belair CD, Savelia E, Puthenveetil JA, and Stadler WM (1996). Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 56, 2886-2890.
41. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, and Hara E (2001). Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409 (6823), 1067-1070.
42. Passegue E and Wagner EF (2000). JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J 19 (12), 2969-2979.
43. Wang XQ, Gabrielli BG, Milligan A, Dickinson JL, Antalis TM, and Ellem KA (1996). Accumulation of p16CDKN2A in response to ultraviolet irradiation correlates with late S-G(2)-phase cell cycle delay. Cancer Res 56 (11), 2510-2514.
44. Shapiro GI, Edwards CD, Ewen ME, and Rollins BJ (1998). p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18 (1), 378-387.
45. Robles SJ and Adami GR (1998). Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 16 (9), 1113-1123.
46. Dai CY and Enders GH (2000). p16 INK4a can initiate an autonomous senescence program. Oncogene 19 (13), 1613-1622.
47. Sharpless NE and DePinho RA (2004). Telomeres. Stem cells, senescence, and cancer. J Clin Invest 113 (2), 160-168.
48. Hermiston ML and Gordon JI (1995). Organization of the crypt-villus axis and evolution of its stem cell hierarchy during intestinal development. Am J Physiol 268 (5 Pt 1), G813-G822.
49. Reya T and Clevers H (2005). Wnt signalling in stem cells and cancer. Nature 434 (7035), 843-850.
50. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, and Clarke MF (2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 (6937), 302-305.
51. Itahana K, Zou Y, Itahana Y, Martinez JL, Beausejour C, Jaccios JJ, Von Lohuizen M, Band V, Campisi J, and Oimri GP (2003). Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 23 (1), 389-401.
52. Brenner AJ, Stampfer MR, and Aldaz CM (1998). Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 17 (2), 199-205.